G17DT Immunogen
- Generic Name
- G17DT Immunogen
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
G17DT Immunogen is a vaccine that neutralizes gastrin-17, a hormone required for the growth of a number of cancers of the gastrointestinal tract. It is in phase III trials for advanced pancreatic cancer as a monotherapy and in combination with gemcitabine. It is also in a phase II/III trial for advanced stomach cancer in combination with 5-fluorouracil and cisplatin and in a late phase II trial for advanced colorectal cancer in combination with irinotecan.
- Indication
Intended for the treatment of various forms of cancer.
- Associated Conditions
- -
- Associated Therapies
- -
Dose-ranging Study to Evaluate Antibody Response to G17DT in Patients With Gastric Cancer
- First Posted Date
- 2015-08-13
- Last Posted Date
- 2015-08-13
- Lead Sponsor
- Cancer Advances Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT02521649
An Open, Single-center Study to Determine the Antibody Repsonse to Gastrimmune and Its Safety and Tolerability in Patients With Advanced Pancreatic Carcinoma
- First Posted Date
- 2014-03-28
- Last Posted Date
- 2014-03-28
- Lead Sponsor
- Cancer Advances Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT02098291
Single Centre Study to Determine the Antibody Response to G17DT in Patients With Advanced Pancreatic Cancer.
- First Posted Date
- 2014-03-27
- Last Posted Date
- 2014-03-27
- Lead Sponsor
- Cancer Advances Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT02098239
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath